{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:40:16Z","timestamp":1770817216578,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00405-024-08495-2","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T15:02:09Z","timestamp":1706972529000},"page":"2037-2040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event"],"prefix":"10.1007","volume":"281","author":[{"given":"Yuki","family":"Ohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-7891","authenticated-orcid":false,"given":"Yushi","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Shodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arata","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"issue":"19","key":"8495_CR1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10212","key":"8495_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"2","key":"8495_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio AD et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479\u2013485. https:\/\/doi.org\/10.1007\/s00432-018-2805-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"8495_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"issue":"6","key":"8495_CR5","doi-asserted-by":"publisher","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","volume":"37","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Takagi T, Kondo T et al (2019) Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 37(6):355.e21-355.e29. https:\/\/doi.org\/10.1016\/j.urolonc.2019.03.003","journal-title":"Urol Oncol"},{"issue":"12","key":"8495_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"8495_CR7","doi-asserted-by":"publisher","first-page":"bcr2017221852","DOI":"10.1136\/bcr-2017-221852","volume":"2017","author":"AK Roy","year":"2017","unstructured":"Roy AK, Tathireddy HR, Roy M (2017) Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep 2017:bcr2017221852. https:\/\/doi.org\/10.1136\/bcr-2017-221852","journal-title":"BMJ Case Rep"},{"issue":"5","key":"8495_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-233496","volume":"13","author":"D Henderson","year":"2020","unstructured":"Henderson D, Eslamian G, Poon D et al (2020) Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Rep 13(5):e233496. https:\/\/doi.org\/10.1136\/bcr-2019-233496","journal-title":"BMJ Case Rep"},{"key":"8495_CR9","doi-asserted-by":"publisher","first-page":"7295305","DOI":"10.1155\/2022\/7295305","volume":"2022","author":"J Mort","year":"2022","unstructured":"Mort J, Maheshwari S, Basu N et al (2022) A rare case of large-vessel vasculitis following checkpoint inhibitor therapy and pegfilgrastim. Case Rep Oncol Med 2022:7295305. https:\/\/doi.org\/10.1155\/2022\/7295305","journal-title":"Case Rep Oncol Med"},{"issue":"15","key":"8495_CR10","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2169\/internalmedicine.8688-21","volume":"61","author":"R Ninomiya","year":"2022","unstructured":"Ninomiya R, Kinehara Y, Tobita S et al (2022) Inflammatory thoracic aortic aneurysm in a patient with advanced lung adenocarcinoma treated with pembrolizumab. Intern Med 61(15):2339\u20132341. https:\/\/doi.org\/10.2169\/internalmedicine.8688-21","journal-title":"Intern Med"},{"key":"8495_CR11","doi-asserted-by":"publisher","first-page":"7971169","DOI":"10.1155\/2022\/7971169","volume":"2022","author":"CH Bloomer","year":"2022","unstructured":"Bloomer CH, Annabathula RV, Aggarwal V, Upadhya B, Lycan TW (2022) A case report of immune checkpoint inhibitor-induced aortitis treated with tocilizumab. Case Reports Immunol 2022:7971169. https:\/\/doi.org\/10.1155\/2022\/7971169","journal-title":"Case Reports Immunol"},{"issue":"23","key":"8495_CR12","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1161\/CIRCULATIONAHA.107.760686","volume":"117","author":"HL Gornik","year":"2008","unstructured":"Gornik HL, Creager MA (2008) Aortitis. Circulation 117(23):3039\u20133051. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.760686","journal-title":"Circulation"},{"issue":"7","key":"8495_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans JM, O\u2019Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 122(7):502\u2013507. https:\/\/doi.org\/10.7326\/0003-4819-122-7-199504010-00004","journal-title":"Ann Intern Med"},{"issue":"4","key":"8495_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","volume":"6","author":"DJ Martini","year":"2018","unstructured":"Martini DJ, Hamieh L, McKay RR et al (2018) Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events. Cancer Immunol Res 6(4):402\u2013408. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0220","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"8495_CR15","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/1759-7714.13149","volume":"10","author":"K Komiya","year":"2019","unstructured":"Komiya K, Nakamura T, Abe T et al (2019) Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 10(9):1798\u20131804. https:\/\/doi.org\/10.1111\/1759-7714.13149","journal-title":"Thorac Cancer"},{"issue":"12","key":"8495_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/00016489.2020.1807601","volume":"140","author":"R Yasumatsu","year":"2020","unstructured":"Yasumatsu R, Matsuo M, Wakasaki T et al (2020) Clinical outcome in recurrent and\/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. Acta Otolaryngol 140(12):1043\u20131048. https:\/\/doi.org\/10.1080\/00016489.2020.1807601","journal-title":"Acta Otolaryngol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08495-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:08:35Z","timestamp":1710504515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08495-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["8495"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08495-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The patients provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}